By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Sarajevo TimesSarajevo TimesSarajevo Times
  • HOME
  • POLITICS
    • BH & EU
  • BUSINESS
  • BH TOURISM
  • INTERVIEWS
    • BH & EU
    • BUSINESS
    • ARTS
  • SPORT
  • ARTS
    • CULTURE
    • ENTERTAINMENT
  • W&N
Search
  • ABOUT US
  • IMPRESSUM
  • NEWSLETTER
  • CONTACT
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Reading: Russian Pharmaceutical Company gets Certification in Bosnia and Herzegovina for Two Medicines
Share
Font ResizerAa
Sarajevo TimesSarajevo Times
Font ResizerAa
  • HOME
  • POLITICS
  • BUSINESS
  • BH TOURISM
  • INTERVIEWS
  • SPORT
  • ARTS
  • W&N
Search
  • HOME
  • POLITICS
    • BH & EU
  • BUSINESS
  • BH TOURISM
  • INTERVIEWS
    • BH & EU
    • BUSINESS
    • ARTS
  • SPORT
  • ARTS
    • CULTURE
    • ENTERTAINMENT
  • W&N
Follow US
  • ABOUT US
  • IMPRESSUM
  • NEWSLETTER
  • CONTACT
© 2012 Sarajevo Times. All rights reserved.
Sarajevo Times > Blog > BUSINESS > Russian Pharmaceutical Company gets Certification in Bosnia and Herzegovina for Two Medicines
BUSINESS

Russian Pharmaceutical Company gets Certification in Bosnia and Herzegovina for Two Medicines

Published: April 6, 2020
Share
SHARE

 

On March 30, 2020, Russian pharmaceutical company, Biocad, announced that it and its partner, ICM d.o.o., recently obtained European registration certification in Bosnia and Herzegovina for two cancer treatment biosimilars:  Acellbia (rituximab), a biosimilar of Roche’s MabThera®, and Herticad (trastuzumab), a biosimilar of Roche’s Herceptin®.  According to Biocad, the registration certificate is valid for five years and initial deliveries are slated to start in June 2020.  Biocad further stated that ICM d.o.o. estimates that the market for these drugs in Bosnia and Herzegovina is $12.7 million.  Biocad’s chief executive, Dmitry Morozov, says the partnership next plans to seek registration in Serbia.

Relatedly, last year the Second Circuit denied Biocad’s Sherman Act antitrust claims against defendants Roche and Genentech for alleged anticompetitive conduct in Russia relating to these biosimilars.  The court found that the Foreign Trade Antitrust Improvements Act of 1982 barred any United States claim because the alleged conduct only resulted in foreign injury and shared no nexus with imports into the United States.

According to the latest data by ICM d.o.o., the market capacity of rituximab and trastuzumab in the country is estimated around $12.7 million. The sales of Russian drugs can start already in June, allowing to decrease government costs for anti-cancer treatment. “By analyzing international markets for launching drugs, we see that our products are in demand,” said Dmitry Morozov, CEO of BIOCAD. “Therefore, in parallel, we conduct registration processes in different countries of Europe. For example, after successful registration in Bosnia and Herzegovina, we are planning to gain access to the Serbian market. These are important steps towards one of the key objectives of our company: to make high-quality therapy available around the world”.

 

Furniture Salon CasaBianca from now in Sarajevo
Interview with Merim Jusufbegovic and Adi Pandzic, BiH Innovators of 3D Printing in Medicine
The new Subdivision of Corridor Vc is open to Traffic
There is no Indication that Fuel Prices will rise in BiH
A Family with three Children and a Baby in their Arms slept in the Cold on the Street
TAGGED:#BiH#medicine#pharmacy#russianBosnia
Share This Article
Facebook Whatsapp Whatsapp Telegram Threads Bluesky Email Print
Share
What do you think?
Love0
Sad0
Happy0
Sleepy0
Angry0
Dead0
Wink0
Previous Article What is the Overall Mine suspected Area in Bosnia and Herzegovina?
Next Article It is Time to think about Life after COVID-19 as the Time doesn’t wait for Anyone
Leave a Comment Leave a Comment

Leave a Reply Cancel reply

You must be logged in to post a comment.

Stay Connected

10.2KFollowersLike
10.1KFollowersFollow
414FollowersFollow

Latest News

Did Milorad Dodik Make a “Cardinal Mistake”? If the Democrats Begin to Investigate, Who Will Stand By Him?
November 14, 2026
DCOM EUFOR Visits Donji Vakuf and Ammunition Storage Site Daljani
November 14, 2026
Barbarez: On Paper, they are certainly stronger, but what do Names matter if the Team doesn’t function?
November 14, 2026
What Will Happen to Electricity Prices for the Economy in 2027?
November 14, 2026
Central Election Commission Makes a Series of Decisions about Mandates
November 14, 2026
Sarajevo Special Forces rank among the World’s best at an International Competition
November 13, 2026
Klinger represents Bosnia and Herzegovina at the World Cup in Uzbekistan
November 13, 2026
Becirovic met with Macron, discussed the Election of a new High Representative
November 13, 2026
Katic and Zlomislic ahead of Solna: The Swedes Are Quality, but We Fear No One
November 13, 2026
The Wine Road of Herzegovina declared the best Wine Event in Europe
November 13, 2026
Sarajevo TimesSarajevo Times
Follow US
© 2012 Sarajevo Times. All Rights Reserved.
  • ABOUT US
  • IMPRESSUM
  • NEWSLETTER
  • CONTACT
Go to mobile version
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?